Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)
Alternative lengthening of telomeres (ALT) supports telomere maintenance in 10-15% of cancers, thus representing a compelling target for therapy. By performing anti-cancer compound library screen on isogenic cell lines and using extrachromosomal telomeric C-circles, as a bona fide marker of ALT acti...
Saved in:
Main Authors: | Kusuma, Frances Karla, Prabhu, Aishvaryaa, Tieo, Galen, Syed Moiz Ahmed, Dakle, Pushkar, Yong, Wai Khang, Pathak, Elina, Madan, Vikas, Jiang, Yan Yi, Tam, Wai Leong, Kappei, Dennis, Dröge, Peter, Koeffler, H. Phillip, Jeitany, Maya |
---|---|
Other Authors: | School of Biological Sciences |
Format: | Article |
Language: | English |
Published: |
2023
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/168369 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas
by: Jeitany, Maya, et al.
Published: (2022) -
FUNCTIONAL CHARACTERIZATION OF HOT1 IN ALT TELOMERE HOMEOSTASIS
by: ALEXIA CHARLINE HILLAIRET
Published: (2023) -
Role of Promyelocytic Leukemia (PML) and Small Ubiquitin-like Modifier (SUMO) Proteins in Alternative Lengthening of Telomeres
by: YONG WEI YAN, JACKLYN
Published: (2011) -
Stable expression of promyelocytic leukaemia (PML) protein in telomerase positive MCF7 cells results in alternative lengthening of telomeres phenotype
by: Yong, J.W.Y., et al.
Published: (2014) -
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
by: Cortes, J.E., et al.
Published: (2016)